U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C15H24O5
Molecular Weight 284.3486
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of .ALPHA.-DIHYDROARTEMISININ

SMILES

C[C@]1([H])CC[C@@]2([H])[C@@]([H])(C)[C@]([H])(O)O[C@@]3([H])[C@]42[C@@]1([H])CC[C@](C)(O3)OO4

InChI

InChIKey=BJDCWCLMFKKGEE-KDTBHNEXSA-N
InChI=1S/C15H24O5/c1-8-4-5-11-9(2)12(16)17-13-15(11)10(8)6-7-14(3,18-13)19-20-15/h8-13,16H,4-7H2,1-3H3/t8-,9-,10+,11+,12-,13-,14-,15-/m1/s1

HIDE SMILES / InChI

Molecular Formula C15H24O5
Molecular Weight 284.3486
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 8 / 8
E/Z Centers 0
Optical Activity UNSPECIFIED

Artesunate (AS) is a medication used to treat malaria. Although not FDA-approved for use in the United States, artesunate is used as the treatment of choice for severe malaria by the World Health Organization (WHO) over quinidine. Upon administration, artesunate is rapidly hydrolyzed to dihydroartemisinin, which is the most active schizonticidal metabolite. In hemoglobin-rich red blood cells, infected by plasmodia, endoperoxide bond of artesunate undergoes cleavage and releases a cascade of reactive intermediates-cytotoxic free radicals, which cause damage to parasites by alkylation of proteins and DNA.

CNS Activity

Curator's Comment:: Active metabolite of artesunate was detected in CSF after intravenous administration of artesunate.

Originator

Sources: http://adisinsight.springer.com/drugs/800023198Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan (1982), 2, (2), 99-103.https://www.ncbi.nlm.nih.gov/pubmed/8891104
Curator's Comment:: Indicated originators are originators of Dihydroartemisinin/piperaquine formulation. Originator of Dihydroartemisinin is unknown.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Sodium artesunate

Approved Use

Plasmodium falciparum malaria
Curative
Eurartesim

Approved Use

Eurartesim tablets (piperaquine tetraphosphate in combination with dihydroartemisinin) are indicated for the treatment of uncomplicated Plasmodium falciparum malaria in adults, children and infants aged ≥6 months and weighing ≥5kg.

Launch Date

1.31958715E12
Curative
Unknown

Approved Use

Although not FDA-approved for use in the United States, artesunate is used as the treatment of choice for severe malaria by the World Health Organization (WHO) over quinidine.
Curative
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.1 μg/mL
2.4 mg/kg multiple, intravenous
dose: 2.4 mg/kg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ARTENIMOL unknown
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
3.3 μg/mL
2.4 mg/kg multiple, intravenous
dose: 2.4 mg/kg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ARTESUNATE unknown
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
3.5 μg × h/mL
2.4 mg/kg multiple, intravenous
dose: 2.4 mg/kg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ARTENIMOL unknown
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
0.7 μg × h/mL
2.4 mg/kg multiple, intravenous
dose: 2.4 mg/kg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ARTESUNATE unknown
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.3 h
2.4 mg/kg multiple, intravenous
dose: 2.4 mg/kg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ARTENIMOL unknown
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
0.3 h
2.4 mg/kg multiple, intravenous
dose: 2.4 mg/kg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ARTESUNATE unknown
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
7%
2.4 mg/kg multiple, intravenous
dose: 2.4 mg/kg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ARTENIMOL unknown
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
7%
2.4 mg/kg multiple, intravenous
dose: 2.4 mg/kg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ARTESUNATE unknown
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2.4 mg/kg 1 times / day multiple, intravenous (complex)
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
n = 92
Health Status: unhealthy
Condition: malaria
Age Group: 1-72 years
Sex: M+F
Population Size: 92
Sources:
Other AEs: Anemia, Transaminases increased...
Other AEs:
Anemia (65%)
Transaminases increased (27%)
Thrombocytopenia (18%)
Hyperbilirubinemia (14%)
Acute renal failure (10%)
Leukocytosis (10%)
Acute respiratory distress syndrome (8%)
Lymphopenia (7%)
Neutropenia (5%)
Disseminated intravascular coagulation (3%)
Creatinine increased (3%)
Pneumonia (3%)
Pulmonary edema (3%)
Diarrhea (3%)
Sources:
100 mg 1 times / day multiple, oral
Studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, 15-35 years
n = 31
Health Status: unhealthy
Condition: Uncomplicated Malaria
Age Group: 15-35 years
Sex: M
Population Size: 31
Sources:
Other AEs: Nausea, Dizziness...
Other AEs:
Nausea (grade 1, 45%)
Dizziness (grade 1, 52%)
Vomiting (grade 1, 26%)
Convulsions (grade 1, 3%)
Bradycardia (grade 1, 23%)
Sources:
2.4 mg/kg 1 times / day multiple, intravenous|oral (complex)
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous|oral
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 2-87 years
n = 730
Health Status: unhealthy
Condition: malaria
Age Group: 2-87 years
Sex: M+F
Population Size: 730
Sources:
Other AEs: Acute renal failure, Hemoglobinuria...
Other AEs:
Acute renal failure (8.9%)
Hemoglobinuria (6.7%)
Jaundice (2.3%)
Sources:
25 mg/kg 2 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 25 mg/kg, 2 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 25 mg/kg, 2 times / 3 weeks
Sources:
unhealthy, 58 years
n = 2
Health Status: unhealthy
Condition: advanced solid tumor malignancies
Age Group: 58 years
Sex: M+F
Population Size: 2
Sources:
DLT: Nausea, Vomiting...
Dose limiting toxicities:
Nausea (grade 3, 1 patient)
Vomiting (grade 3, 1 patient)
ALT increased (grade 3-4, 1 patient)
Neutropenic infection (grade 3-4, 1 patient)
Sources:
18 mg/kg 2 times / 3 weeks multiple, intravenous
MTD
Dose: 18 mg/kg, 2 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 18 mg/kg, 2 times / 3 weeks
Sources:
unhealthy, 58 years
n = 6
Health Status: unhealthy
Condition: advanced solid tumor malignancies
Age Group: 58 years
Sex: M+F
Population Size: 6
Sources:
DLT: Hypersensitivity reaction...
Dose limiting toxicities:
Hypersensitivity reaction (grade 3, 1 patient)
Sources:
12 mg/kg 2 times / 3 weeks multiple, intravenous
Studied dose
Dose: 12 mg/kg, 2 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 12 mg/kg, 2 times / 3 weeks
Sources:
unhealthy, 58 years
n = 6
Health Status: unhealthy
Condition: advanced solid tumor malignancies
Age Group: 58 years
Sex: M+F
Population Size: 6
Sources:
DLT: Neutropenic fever...
Dose limiting toxicities:
Neutropenic fever (grade 3, 1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Acute renal failure 10%
2.4 mg/kg 1 times / day multiple, intravenous (complex)
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
n = 92
Health Status: unhealthy
Condition: malaria
Age Group: 1-72 years
Sex: M+F
Population Size: 92
Sources:
Leukocytosis 10%
2.4 mg/kg 1 times / day multiple, intravenous (complex)
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
n = 92
Health Status: unhealthy
Condition: malaria
Age Group: 1-72 years
Sex: M+F
Population Size: 92
Sources:
Hyperbilirubinemia 14%
2.4 mg/kg 1 times / day multiple, intravenous (complex)
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
n = 92
Health Status: unhealthy
Condition: malaria
Age Group: 1-72 years
Sex: M+F
Population Size: 92
Sources:
Thrombocytopenia 18%
2.4 mg/kg 1 times / day multiple, intravenous (complex)
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
n = 92
Health Status: unhealthy
Condition: malaria
Age Group: 1-72 years
Sex: M+F
Population Size: 92
Sources:
Transaminases increased 27%
2.4 mg/kg 1 times / day multiple, intravenous (complex)
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
n = 92
Health Status: unhealthy
Condition: malaria
Age Group: 1-72 years
Sex: M+F
Population Size: 92
Sources:
Creatinine increased 3%
2.4 mg/kg 1 times / day multiple, intravenous (complex)
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
n = 92
Health Status: unhealthy
Condition: malaria
Age Group: 1-72 years
Sex: M+F
Population Size: 92
Sources:
Diarrhea 3%
2.4 mg/kg 1 times / day multiple, intravenous (complex)
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
n = 92
Health Status: unhealthy
Condition: malaria
Age Group: 1-72 years
Sex: M+F
Population Size: 92
Sources:
Disseminated intravascular coagulation 3%
2.4 mg/kg 1 times / day multiple, intravenous (complex)
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
n = 92
Health Status: unhealthy
Condition: malaria
Age Group: 1-72 years
Sex: M+F
Population Size: 92
Sources:
Pneumonia 3%
2.4 mg/kg 1 times / day multiple, intravenous (complex)
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
n = 92
Health Status: unhealthy
Condition: malaria
Age Group: 1-72 years
Sex: M+F
Population Size: 92
Sources:
Pulmonary edema 3%
2.4 mg/kg 1 times / day multiple, intravenous (complex)
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
n = 92
Health Status: unhealthy
Condition: malaria
Age Group: 1-72 years
Sex: M+F
Population Size: 92
Sources:
Neutropenia 5%
2.4 mg/kg 1 times / day multiple, intravenous (complex)
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
n = 92
Health Status: unhealthy
Condition: malaria
Age Group: 1-72 years
Sex: M+F
Population Size: 92
Sources:
Anemia 65%
2.4 mg/kg 1 times / day multiple, intravenous (complex)
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
n = 92
Health Status: unhealthy
Condition: malaria
Age Group: 1-72 years
Sex: M+F
Population Size: 92
Sources:
Lymphopenia 7%
2.4 mg/kg 1 times / day multiple, intravenous (complex)
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
n = 92
Health Status: unhealthy
Condition: malaria
Age Group: 1-72 years
Sex: M+F
Population Size: 92
Sources:
Acute respiratory distress syndrome 8%
2.4 mg/kg 1 times / day multiple, intravenous (complex)
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
n = 92
Health Status: unhealthy
Condition: malaria
Age Group: 1-72 years
Sex: M+F
Population Size: 92
Sources:
Bradycardia grade 1, 23%
100 mg 1 times / day multiple, oral
Studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, 15-35 years
n = 31
Health Status: unhealthy
Condition: Uncomplicated Malaria
Age Group: 15-35 years
Sex: M
Population Size: 31
Sources:
Vomiting grade 1, 26%
100 mg 1 times / day multiple, oral
Studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, 15-35 years
n = 31
Health Status: unhealthy
Condition: Uncomplicated Malaria
Age Group: 15-35 years
Sex: M
Population Size: 31
Sources:
Convulsions grade 1, 3%
100 mg 1 times / day multiple, oral
Studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, 15-35 years
n = 31
Health Status: unhealthy
Condition: Uncomplicated Malaria
Age Group: 15-35 years
Sex: M
Population Size: 31
Sources:
Nausea grade 1, 45%
100 mg 1 times / day multiple, oral
Studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, 15-35 years
n = 31
Health Status: unhealthy
Condition: Uncomplicated Malaria
Age Group: 15-35 years
Sex: M
Population Size: 31
Sources:
Dizziness grade 1, 52%
100 mg 1 times / day multiple, oral
Studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, 15-35 years
n = 31
Health Status: unhealthy
Condition: Uncomplicated Malaria
Age Group: 15-35 years
Sex: M
Population Size: 31
Sources:
Jaundice 2.3%
2.4 mg/kg 1 times / day multiple, intravenous|oral (complex)
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous|oral
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 2-87 years
n = 730
Health Status: unhealthy
Condition: malaria
Age Group: 2-87 years
Sex: M+F
Population Size: 730
Sources:
Hemoglobinuria 6.7%
2.4 mg/kg 1 times / day multiple, intravenous|oral (complex)
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous|oral
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 2-87 years
n = 730
Health Status: unhealthy
Condition: malaria
Age Group: 2-87 years
Sex: M+F
Population Size: 730
Sources:
Acute renal failure 8.9%
2.4 mg/kg 1 times / day multiple, intravenous|oral (complex)
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous|oral
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 2-87 years
n = 730
Health Status: unhealthy
Condition: malaria
Age Group: 2-87 years
Sex: M+F
Population Size: 730
Sources:
Nausea grade 3, 1 patient
DLT
25 mg/kg 2 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 25 mg/kg, 2 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 25 mg/kg, 2 times / 3 weeks
Sources:
unhealthy, 58 years
n = 2
Health Status: unhealthy
Condition: advanced solid tumor malignancies
Age Group: 58 years
Sex: M+F
Population Size: 2
Sources:
Vomiting grade 3, 1 patient
DLT
25 mg/kg 2 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 25 mg/kg, 2 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 25 mg/kg, 2 times / 3 weeks
Sources:
unhealthy, 58 years
n = 2
Health Status: unhealthy
Condition: advanced solid tumor malignancies
Age Group: 58 years
Sex: M+F
Population Size: 2
Sources:
ALT increased grade 3-4, 1 patient
DLT
25 mg/kg 2 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 25 mg/kg, 2 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 25 mg/kg, 2 times / 3 weeks
Sources:
unhealthy, 58 years
n = 2
Health Status: unhealthy
Condition: advanced solid tumor malignancies
Age Group: 58 years
Sex: M+F
Population Size: 2
Sources:
Neutropenic infection grade 3-4, 1 patient
DLT
25 mg/kg 2 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 25 mg/kg, 2 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 25 mg/kg, 2 times / 3 weeks
Sources:
unhealthy, 58 years
n = 2
Health Status: unhealthy
Condition: advanced solid tumor malignancies
Age Group: 58 years
Sex: M+F
Population Size: 2
Sources:
Hypersensitivity reaction grade 3, 1 patient
DLT
18 mg/kg 2 times / 3 weeks multiple, intravenous
MTD
Dose: 18 mg/kg, 2 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 18 mg/kg, 2 times / 3 weeks
Sources:
unhealthy, 58 years
n = 6
Health Status: unhealthy
Condition: advanced solid tumor malignancies
Age Group: 58 years
Sex: M+F
Population Size: 6
Sources:
Neutropenic fever grade 3, 1 patient
DLT
12 mg/kg 2 times / 3 weeks multiple, intravenous
Studied dose
Dose: 12 mg/kg, 2 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 12 mg/kg, 2 times / 3 weeks
Sources:
unhealthy, 58 years
n = 6
Health Status: unhealthy
Condition: advanced solid tumor malignancies
Age Group: 58 years
Sex: M+F
Population Size: 6
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
weak [IC50 32.3 uM]
weak [IC50 75.4 uM]
yes
yes
Drug as victimTox targets

Tox targets

PubMed

PubMed

TitleDatePubMed
Antimalarial agents, 2. Artesunate, an inhibitor of cytochrome oxidase activity in Plasmodium berghei.
1986 Jan-Feb
[Effects of sodium artesunate on electrical properties and Na+,K(+)-ATPase activities of mouse small intestine].
1990 Jul
Monotherapy with sodium artesunate for uncomplicated falciparum malaria in Thailand: a comparison of 5- and 7-day regimens.
1997 Sep 30
Effects of sodium artesunate, a new antimalarial drug, on renal function.
2001 Mar
Diuretic effect of sodium artesunate in patients with malaria.
2002 Nov
Penetration of dihydroartemisinin into cerebrospinal fluid after administration of intravenous artesunate in severe falciparum malaria.
2003 Jan
Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data.
2003 Sep
Artesunate in the treatment of metastatic uveal melanoma--first experiences.
2005 Dec
Mechanistic perspectives for 1,2,4-trioxanes in anti-cancer therapy.
2005 Feb-Apr
Glutathione-related enzymes contribute to resistance of tumor cells and low toxicity in normal organs to artesunate.
2005 Jan-Feb
Adding artesunate to sulphadoxine-pyrimethamine greatly improves the treatment efficacy in children with uncomplicated falciparum malaria on the coast of Benin, West Africa.
2007 Dec 21
Treatment of experimental nephrotic syndrome with artesunate.
2007 Jul-Aug
Auditory assessment of patients with acute uncomplicated Plasmodium falciparum malaria treated with three-day mefloquine-artesunate on the north-western border of Thailand.
2008 Nov 6
Combination treatment of malignant B cells using the anti-CD20 antibody rituximab and the anti-malarial artesunate.
2009 Jul
In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals.
2010 May
Artesunate-mefloquine combination therapy in acute Plasmodium falciparum malaria in young children: a field study regarding neurological and neuropsychiatric safety.
2010 Oct 21
Artesunate induces apoptosis through caspase-dependent and -independent mitochondrial pathways in human myelodysplastic syndrome SKM-1 cells.
2014 Aug 5
Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria.
2014 Jan 20
Delayed anemia after treatment with injectable artesunate in the Democratic Republic of the Congo: a manageable issue.
2014 Oct
Utilization of human nuclear receptors as an early counter screen for off-target activity: a case study with a compendium of 615 known drugs.
2015 Jun
Untargeted Proteomics and Systems-Based Mechanistic Investigation of Artesunate in Human Bronchial Epithelial Cells.
2015 Oct 19
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: Oral route is possible: One group of 45 patients received 400 mg of Sodium artesunate on the first day of treatment and then 200 mg daily for 4 days for a total of 1200 mg (group I: 5-day treatment). A second group of 46 patients received 400 mg of Sodium artesunate on the first day of treatment and then 200 mg daily for 6 days for a total of 1600 mg (group II: 7-day treatment). 5- or 7-day regimens of sodium artesunate with a total dose of 1200-1600 mg are effective and safe in treating falciparum malaria acquired in Thailand. https://www.ncbi.nlm.nih.gov/pubmed/9241384
Eurartesim (piperaquine tetraphosphate (PQP)/ dihydroartemisinin (DHA)) should be taken over 3 consecutive days for a total of three doses taken at the same time each day. The tablets are available in two strengths: PQP 160mg/DHA 20mg and PQP 320mg/DHA 40mg. The dose is determined by the patient’s body weight.
Route of Administration: Oral
dihydroartemisinin at micromolar dose levels exhibits a dose- and time-dependent cytotoxicity in ovarian cancer cell lines.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:55:07 UTC 2021
Edited
by admin
on Fri Jun 25 21:55:07 UTC 2021
Record UNII
X0UIV26ABX
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
.ALPHA.-DIHYDROARTEMISININ
Common Name English
DIHYDROARTIMISININ
Common Name English
3,12-EPOXY-12H-PYRANO(4,3-J)-1,2-BENZODIOXEPIN-10-OL, DECAHYDRO-3,6,9-TRIMETHYL-, (3R,5AS,6R,8AS,9R,10R,12R,12AR)-
Common Name English
3,12-EPOXY-12H-PYRANO(4,3-J)-1,2-BENZODIOXEPIN-10-OL, DECAHYDRO-3,6,9-TRIMETHYL-, (3R-(3.ALPHA.,5A.BETA.,6.BETA.,8A.BETA.,9.ALPHA.,10.BETA.,12.BETA.,12AR*))-
Common Name English
NSC-758682
Code English
Code System Code Type Description
CAS
81496-81-3
Created by admin on Fri Jun 25 21:55:07 UTC 2021 , Edited by admin on Fri Jun 25 21:55:07 UTC 2021
PRIMARY
DRUG BANK
DBMET00793
Created by admin on Fri Jun 25 21:55:07 UTC 2021 , Edited by admin on Fri Jun 25 21:55:07 UTC 2021
PRIMARY
PUBCHEM
11358077
Created by admin on Fri Jun 25 21:55:07 UTC 2021 , Edited by admin on Fri Jun 25 21:55:07 UTC 2021
PRIMARY
FDA UNII
X0UIV26ABX
Created by admin on Fri Jun 25 21:55:07 UTC 2021 , Edited by admin on Fri Jun 25 21:55:07 UTC 2021
PRIMARY
EPA CompTox
81496-81-3
Created by admin on Fri Jun 25 21:55:07 UTC 2021 , Edited by admin on Fri Jun 25 21:55:07 UTC 2021
PRIMARY
Related Record Type Details
BINDER->LIGAND
Related Record Type Details
PRODRUG -> METABOLITE ACTIVE
ratio of alpha to beta DIHYDROARTEMISININ is 3.5
PLASMA
PARENT -> METABOLITE